ZEAL Stock Analysis Today
Updated Nov 13, 2026 · trends, key levels, insider activity and news
Is ZEAL bullish or bearish today?
SEPT signal: No data · Consolidating
ZEAL trend by timeframe
| 4 hour | No data |
|---|---|
| 1 hour | No data |
| 15 min | No data |
| 5 min | No data |
Trends are calculated from price structure and update during market hours.
Latest ZEAL news and filings
- ProductFiscal.ai
Zealand Pharma secures European approval for its drug Zeydovio (glepaglutide)
Regulators in Europe have cleared Zealand Pharma's medicine Zeydovio, also called glepaglutide, for sale. This lets the company start selling the treatment across European countries.
- ProductBenzinga
Zealand Pharma receives EU marketing authorization for Zeydovio in short bowel syndrome
The European Commission has approved Zeydovio, a long-acting next-generation GLP-2 analog from Zealand Pharma, for treating adults with short bowel syndrome.
- DealFiscal.ai
Zealand Pharma restarts glepaglutide partnering discussions, CFO says
Zealand Pharma has begun again its search for a collaborator on glepaglutide, per the finance chief. The company is talking with possible partners about the drug.
- EarningsFiscal.ai
Zealand Pharma posts financial results for 2026 period ending in September
Zealand Pharma published its financial results for the year-to-date period through September 2026. The report covers the company's performance during those months.
- ProductFiscal.ai
Zealand Pharma reports positive Phase 1 topline results for ZP9830
Zealand Pharma said its Phase 1 trial of ZP9830 produced positive topline results. The trial is an early-stage study of the drug candidate.
Live ZEAL chart with trend icons on every timeframe, key levels, dark pool and options flow, news alerts, and Ask GOAX for a full analysis on demand.
Start free 7-day trialFrequently asked questions
Why is ZEAL stock moving today?
Nov 13, 2026: Zealand Pharma secured European Commission approval for its drug Zeydovio (glepaglutide), a long-acting next-generation GLP-2 analog for treating adults with short bowel syndrome. This regulatory clearance allows the company to begin selling the treatment across European countries.
Is ZEAL bullish or bearish today?
SEPT signal: No data (Consolidating). Updated Nov 13, 2026.
What is ZEAL's trend on each timeframe?
4 hour: No data; 1 hour: No data; 15 min: No data; 5 min: No data.
What is the latest news on ZEAL?
Nov 13, 2026: Zealand Pharma secures European approval for its drug Zeydovio (glepaglutide) · Nov 13, 2026: Zealand Pharma receives EU marketing authorization for Zeydovio in short bowel syndrome · Nov 12, 2026: Zealand Pharma restarts glepaglutide partnering discussions, CFO says